Literature DB >> 23211289

Phospho-ERK(THR202/Tyr214) is overexpressed in hairy cell leukemia and is a useful diagnostic marker in bone marrow trephine sections.

Douglas W Warden1, Sarah Ondrejka, Jeffrey Lin, Lisa Durkin, Juraj Bodo, Eric D Hsi.   

Abstract

BRAF V600E mutations are present in virtually all cases of hairy cell leukemia (HCL). We hypothesized that detection of phospho-ERK (pERK) in tissue sections may be a useful marker for diagnosis of HCL. pERK/CD20 double immunostaining was performed on 90 formalin-fixed bone marrow trephine samples affected with small B-cell lymphoproliferative disorders, including 28 cases of HCL. pERK staining was observed in all 28 cases of HCL and in 1 of 62 cases of non-HCL B-cell lymphoproliferative disorders. By allele-specific polymerase chain reaction, all 11 cases of HCL with available DNA were positive for BRAF V600E, as was the 1 pERK non-HCL case. The remaining 31 non-HCL cases tested were negative for BRAF V600E. The sensitivity and specificity of pERK for diagnosis of HCL was 100% and 98%, respectively. We conclude that the presence of pERK as detected by immunohistochemical staining is a useful surrogate marker for BRAF V600E in the diagnosis of HCL.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23211289     DOI: 10.1097/PAS.0b013e3182712481

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  7 in total

1.  Frequent BRAF V600E and Absence of TERT Promoter Mutations Characterize Sporadic Pediatric Papillary Thyroid Carcinomas in Japan.

Authors:  Naoki Oishi; Tetsuo Kondo; Tadao Nakazawa; Kunio Mochizuki; Tomohiro Inoue; Kazunari Kasai; Ippei Tahara; Tomonori Yabuta; Mitsuyoshi Hirokawa; Akira Miyauchi; Ryohei Katoh
Journal:  Endocr Pathol       Date:  2017-06       Impact factor: 3.943

2.  Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia.

Authors:  Enrico Tiacci; Jae H Park; Luca De Carolis; Stephen S Chung; Alessandro Broccoli; Sasinya Scott; Francesco Zaja; Sean Devlin; Alessandro Pulsoni; Young R Chung; Michele Cimminiello; Eunhee Kim; Davide Rossi; Richard M Stone; Giovanna Motta; Alan Saven; Marzia Varettoni; Jessica K Altman; Antonella Anastasia; Michael R Grever; Achille Ambrosetti; Kanti R Rai; Vincenzo Fraticelli; Mario E Lacouture; Angelo M Carella; Ross L Levine; Pietro Leoni; Alessandro Rambaldi; Franca Falzetti; Stefano Ascani; Monia Capponi; Maria P Martelli; Christopher Y Park; Stefano A Pileri; Neal Rosen; Robin Foà; Michael F Berger; Pier L Zinzani; Omar Abdel-Wahab; Brunangelo Falini; Martin S Tallman
Journal:  N Engl J Med       Date:  2015-09-09       Impact factor: 91.245

3.  BRAF V600E-Negative Hairy Cell Leukaemia.

Authors:  Stephen E Langabeer; David O'Brien; Anthony M McElligott; Michelle Lavin; Paul V Browne
Journal:  Case Rep Hematol       Date:  2013-04-09

4.  Potential role of AKT/mTOR signalling proteins in hairy cell leukaemia: association with BRAF/ERK activation and clinical outcome.

Authors:  Eleftheria Lakiotaki; Georgia Levidou; Maria K Angelopoulou; Christos Adamopoulos; Gerassimos Pangalis; George Rassidakis; Theodoros Vassilakopoulos; Gabriella Gainaru; Pagona Flevari; Sotirios Sachanas; Angelica A Saetta; Athanasia Sepsa; Maria Moschogiannis; Christina Kalpadakis; Nikolaos Tsesmetzis; Vassilios Milionis; Ilenia Chatziandreou; Irene Thymara; Panayiotis Panayiotidis; Maria Dimopoulou; Eleni Plata; Konstantinos Konstantopoulos; Efstratios Patsouris; Christina Piperi; Penelope Korkolopoulou
Journal:  Sci Rep       Date:  2016-02-19       Impact factor: 4.379

Review 5.  Genomics of Hairy Cell Leukemia.

Authors:  Enrico Tiacci; Valentina Pettirossi; Gianluca Schiavoni; Brunangelo Falini
Journal:  J Clin Oncol       Date:  2017-02-13       Impact factor: 44.544

6.  Mutations in the RAS-BRAF-MAPK-ERK pathway define a specific subgroup of patients with adverse clinical features and provide new therapeutic options in chronic lymphocytic leukemia.

Authors:  Neus Giménez; Alejandra Martínez-Trillos; Arnau Montraveta; Mónica Lopez-Guerra; Laia Rosich; Ferran Nadeu; Juan G Valero; Marta Aymerich; Laura Magnano; Maria Rozman; Estella Matutes; Julio Delgado; Tycho Baumann; Eva Gine; Marcos González; Miguel Alcoceba; M José Terol; Blanca Navarro; Enrique Colado; Angel R Payer; Xose S Puente; Carlos López-Otín; Armando Lopez-Guillermo; Elias Campo; Dolors Colomer; Neus Villamor
Journal:  Haematologica       Date:  2018-09-27       Impact factor: 9.941

7.  Hairy cell leukemia: short review, today's recommendations and outlook.

Authors:  V Maevis; U Mey; G Schmidt-Wolf; I G H Schmidt-Wolf
Journal:  Blood Cancer J       Date:  2014-02-14       Impact factor: 11.037

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.